Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 9/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16720727 | 0.81 | MAPT (0.81) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL28671523 | 0.80 | PPARG (0.61) | ALDH1A1MAPTKDM4EPPARGMEN1 | |
| SCHEMBL7246369 | 0.80 | PPARG (0.61) | ALDH1A1MAPTKDM4EPPARGMEN1 | |
| SCHEMBL12452461 | 0.79 | MAPT (0.59) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL18966724 | 0.78 | ALDH1A1 (0.56) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL7974481 | 0.77 | PPARG (0.55) | ALDH1A1MAPTKDM4EPPARGMEN1 | |
| SCHEMBL6071011 | 0.77 | MAPT (0.58) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL5272318 | 0.77 | AXL (0.57) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL8999779 | 0.77 | MAPT (0.57) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL16412962 | 0.77 | PPARG (0.57) | ALDH1A1MAPTKDM4EPPARGMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4234544-A1 | FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | Generos Biopharma Ltd. (KY) | 2023-08-30 | — | — | EP | disclosed |
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-04-02 | — | — | US | disclosed |
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-04 | — | — | US | disclosed |
| EP-3194374-B1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-08-01 | — | — | EP | disclosed |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-19 | — | — | US | disclosed |
| US-9932314-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-03 | — | — | US | disclosed |
| EP-3152199-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | Actelion Pharmaceuticals Ltd. (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-06 | — | — | US | disclosed |
| WO-2015186056-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | CACNA1E, CACNA1I, CACNA1G | ALDH1A1 3435/4885MAPT 1301/4885KDM4E 3649/4885 |
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | CACNA1I, CACNA1E, CACNA1G | ALDH1A1 3606/4885MAPT 1351/4885KDM4E 3001/4885 |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | ALDH1A1 3435/4885MAPT 1301/4885KDM4E 3649/4885 |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | ALDH1A1 3435/4885MAPT 1301/4885KDM4E 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.